Oral metabolic franchise, a broader portfolio of oral small molecule candidates targeting metabolic disease beyond the lead GLP-1 program Recent Highlights: In May 2026, Structure reported positive end-of-Phase 2 feedback from the FDA for aleniglipron, clearing the way to begin a Phase 3 registrational program for chronic weight management in Q3 2026
This may be explained by enhanced cellular uptake, penetration, and sustained release
ABCC1-mediated GSH efflux can paradoxically sensitize cells to ferroptosis by depleting intracellular GSH 146
The effect of vitamin d supplementation on insulin resistance, visceral fat and adiponectin in vitamin d deficient women with polycystic ovary syndrome: A randomized placebo-controlled trial
Picking between them, or stacking them, should come down to how each one actually works, not just habit or whatever you've seen other people running